Stocktoria
Sagimet Biosciences Inc. SGMT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-07-14
Sagimet Biosciences Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | $2.0M | — |
| R&D expense | $39.1M | $38.4M | $19.8M | $24.9M |
| Operating income | -$56.9M | -$54.5M | -$30.7M | -$31.1M |
| Income tax | $0 | $0 | — | — |
| Net income | -$51.0M | -$45.6M | -$27.9M | -$30.5M |
| EPS (diluted) | $-1.58 | $-1.45 | $-2.66 | $-165.20 |
| Operating cash flow | -$45.6M | -$42.4M | -$23.8M | -$24.5M |
| Cash & equivalents | $35.0M | $75.8M | $75.1M | $158,000 |
| Total assets | $116.5M | $160.3M | $96.7M | $33.0M |
| Total liabilities | — | $4.5M | $5.7M | $5.4M |
| Shareholders' equity | $111.4M | $155.8M | $91.1M | -$186.9M |
Source: SEC EDGAR filings · CIK 0001400118 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.